Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
Yen Ying Lim(The University of Melbourne), Akinori Nakamura(National Center for Geriatrics and Gerontology), Christopher C. Rowe(The University of Melbourne), Naoki Kaneko(University of California, Los Angeles), Colin L. Masters(Mental Health Research Institute), Katsuhiko Yanagisawa(National Center for Geriatrics and Gerontology), Victor L. Villemagne(The University of Melbourne), Paul Maruff(The University of Melbourne), Yutaka Arahata(National Center for Geriatrics and Gerontology), Shinichi Iwamoto, Christopher Fowler(Florey Institute of Neuroscience and Mental Health), Kengo Ito(National Center for Geriatrics and Gerontology), Takashi Kato(National Center for Geriatrics and Gerontology), Kōichi Tanaka(Keio University), James D. Doecke(Royal Brisbane and Women's Hospital)
Cited by 54
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k